Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy

被引:0
|
作者
Cazzola, M [1 ]
Ponchio, L [1 ]
Pedrotti, C [1 ]
Farina, G [1 ]
Cerani, P [1 ]
Lucotti, C [1 ]
Novella, A [1 ]
Rovati, A [1 ]
Bergamaschi, G [1 ]
Beguin, Y [1 ]
机构
[1] UNIV LIEGE,DEPT MED,DIV HEMATOL,LIEGE,BELGIUM
关键词
anemia; erythropoietin; prediction; reticulocyte; transferrin receptor;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Since only a portion of anemic patients outside the uremia setting benefit from erythropoietin treatment, a reliable means of predicting potential responders and nonresponders would be very useful. Materials and Methods. We retrospectively reviewed the clinical records of 58 patients with refractory anemia associated with various malignant disorders who had been treated with subcutaneous rHuEpo. The starting rHuEpo dose was 375 U/kg/week for 4 weeks, and was increased to 750 U/kg/week for another 4 weeks if no response was observed. Response was defined as a Hb increase greater than or equal to 2 g/dL with no need for blood transfusion. We examined the value of various laboratory parameters (baseline levels, 2-week and 4-week changes) as predictors of response. Endogenous erythropoietin production was evaluated by its serum level and erythroid activity was assessed through reticulocyte count and circulating transferrin receptor. Results. Forty-eight individuals were evaluable, 58% of whom responded to rHuEpo within 8 weeks. Multiple regression analysis showed that 53% of the variation in the 8-week Hb concentration was explained by variations in baseline serum erythropoietin and the 2-week change in serum transferrin receptor (p < 0.001). Based on these two parameters, response prediction in individual patients would have resulted in a sensitivity of 96%, a specificity of 79% and an overall accuracy of 88%. In addition, 58% of the variation in the 8-week Hb was explained by variations in the 4-week changes in Hb and reticulocyte count (p < 0.001). Utilizing these latter parameters and baseline serum erythropoietin, response prediction in individual patients would have resulted in a sensitivity of 92%, a specificity of 82% and an overall accuracy of 88%. Conclusions. This retrospective analysis suggests that response to rHuEpo can be reasonably predicted by pretreatment serum erythropoietin together with early changes in simple laboratory parameters.
引用
收藏
页码:434 / 441
页数:8
相关论文
共 50 条
  • [1] Secondary anemia after cessation of treatment with recombinant human erythropoietin (rHuEpo).
    Loo, M
    Fillet, G
    Beguin, Y
    [J]. BLOOD, 1996, 88 (10) : 568 - 568
  • [2] DESFERRIOXAMINE (DFO) ENHANCES THE RESPONSE TO HUMAN RECOMBINANT ERYTHROPOIETIN (RHUEPO)
    ROGER, SD
    STEWART, JH
    HARRIS, DCH
    [J]. KIDNEY INTERNATIONAL, 1990, 38 (03) : 545 - 546
  • [3] Recombinant human erythropoietin (rHuEPO): More than just the correction of uremic anemia
    Buemi, M
    Aloisi, C
    Cavallaro, E
    Corica, F
    Floccari, F
    Grasso, G
    Lasco, A
    Pettinato, G
    Ruello, A
    Sturiale, A
    Frisina, N
    [J]. JOURNAL OF NEPHROLOGY, 2002, 15 (02) : 97 - 103
  • [4] Anemia in premature infant and treatment by recombinant human erythropoietin (rHuEPO): which benefit?
    Klosowski, S
    Djebara, A
    Bachiri, A
    Haouari, N
    Thelliez, R
    Morisot, C
    [J]. ARCHIVES DE PEDIATRIE, 2001, 8 (12): : 1400 - 1402
  • [5] Recombinant human erythropoietin (rHuEPO) in the treatment of chronic anemia in pediatric cancer and chemotherapy
    Dornbusch, P
    Urban, C
    Thalmann, E
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 1023 - 1023
  • [6] CORRECTION OF ANEMIA IN PROGRESSIVE RENAL-FAILURE WITH RECOMBINANT HUMAN ERYTHROPOIETIN (RHUEPO)
    ESCHBACH, JW
    KELLY, MR
    HALEY, NR
    ABELS, RI
    ADAMSON, JW
    [J]. KIDNEY INTERNATIONAL, 1989, 35 (01) : 193 - 193
  • [7] TREATMENT OF UREMIC ANEMIA WITH ETRETINATE - COMPARISON WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO)
    LAMPERI, S
    CAROZZI, S
    ICARDI, A
    NASINI, MG
    TRAVERSO, GB
    [J]. CURRENT THERAPY IN NEPHROLOGY, 1989, 24 : 158 - 160
  • [8] THERAPY OF RENAL ANEMIA IN CHILDREN AND ADOLESCENTS WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO)
    CAMPOS, A
    GARIN, EH
    [J]. CLINICAL PEDIATRICS, 1992, 31 (02) : 94 - 99
  • [9] THERAPY OF RENAL ANEMIA IN CHILDREN AND ADOLESCENTS WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO)
    CAMPOS, A
    GARIN, EH
    [J]. PEDIATRIC RESEARCH, 1990, 27 (04) : A326 - A326
  • [10] Cessation of intensive treatment with recombinant human erythropoietin (rHuEpo) is followed by secondary anemia
    Piron, M
    Loo, M
    Gothot, A
    Tassin, F
    Fillet, G
    Beguin, Y
    [J]. EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 55 - 55